ABVC

ABVC BioPharma (ABVC)

ABVC BioPharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ABVC

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/18	06 : 00	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/05/18	05 : 01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/05/16	06 : 00	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:ABVC	ABVC BioPharma Inc
2024/05/15	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/05/09	22 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/04/18	22 : 25	GlobeNewswire Inc.	AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share	NASDAQ:ABVC	ABVC BioPharma Inc
2024/04/17	22 : 00	GlobeNewswire Inc.	ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	NASDAQ:ABVC	ABVC BioPharma Inc
2024/04/10	21 : 30	GlobeNewswire Inc.	ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M	NASDAQ:ABVC	ABVC BioPharma Inc
2024/03/26	21 : 30	GlobeNewswire Inc.	ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M	NASDAQ:ABVC	ABVC BioPharma Inc
2024/03/21	21 : 30	GlobeNewswire Inc.	AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars	NASDAQ:ABVC	ABVC BioPharma Inc
2024/03/19	21 : 30	GlobeNewswire Inc.	ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine	NASDAQ:ABVC	ABVC BioPharma Inc
2024/03/14	22 : 30	GlobeNewswire Inc.	ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update	NASDAQ:ABVC	ABVC BioPharma Inc
2024/03/01	06 : 32	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/03/01	06 : 31	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/27	22 : 30	GlobeNewswire Inc.	ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/17	07 : 04	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/15	22 : 30	GlobeNewswire Inc.	ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/14	09 : 59	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/12	22 : 30	GlobeNewswire Inc.	ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/10	07 : 04	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/08	23 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/02/08	23 : 17	GlobeNewswire Inc.	ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share	NASDAQ:ABVC	ABVC BioPharma Inc
2024/01/18	07 : 01	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ABVC	ABVC BioPharma Inc
2024/01/18	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/01/18	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ABVC	ABVC BioPharma Inc
2024/01/13	07 : 01	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:ABVC	ABVC BioPharma Inc
2024/01/03	21 : 24	GlobeNewswire Inc.	ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees	NASDAQ:ABVC	ABVC BioPharma Inc
2023/12/07	22 : 30	GlobeNewswire Inc.	ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study	NASDAQ:ABVC	ABVC BioPharma Inc
2023/12/05	22 : 30	GlobeNewswire Inc.	ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials	NASDAQ:ABVC	ABVC BioPharma Inc
2023/11/21	22 : 30	GlobeNewswire Inc.	ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market	NASDAQ:ABVC	ABVC BioPharma Inc